Organogenesis Holdings Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Organogenesis reported Q3 2026 net revenue of $45.5M (down $105.0M or 70% from Q3 2025's $150.5M), driven by a 73% decline in Advanced Wound Care revenue ($38.2M vs. $141.5M). The company swung to a net loss of $29.6M (vs. $21.6M profit in Q3 2025). Nine-month 2026 results show net loss of $179.1M (vs. $6.7M loss in nine months 2025). Cash declined to $26.9M (Sept 30, 2026) from $94.3M (Dec 31, 2025). Full-year 2026 guidance: $179.4M–$200.0M revenue (65–68% decline vs. 2025's $564.2M). The company cites a 'market reset' in Advanced Wound Care but claims sequential improvement and market share gains.
Why this rating
Revenue collapse of $213.4M YTD (63%) and loss swing of $172.4M represent >50% of $299M market cap. Cash burn acute; liquidity eroding. Business trajectory severely compromised; ongoing market pressure in core segment.
Tradability signal
SHORT
conviction 39/100 · expected -1.69% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (271 in this cell) moved +1.85% in the called direction over 4 hrs; shrunk for sample size that's a +1.69% edge. Price is up 7.1% since the filing hit EDGAR — market hasn't digested it yet. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.76 ▼ 3.48% | at our read · unknown $0.79 | +10 min · unknown $0.85 ▲ 7.60% | +30 min · unknown $0.85 ▲ 7.96% | +1 hr · unknown $0.87 ▲ 10.20% | +4 hrs · unknown $0.89 ▲ 12.41% |
The stock had already moved +3.61% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.